New York State Teachers Retirement System Reduces Position in Haemonetics Co. (NYSE:HAE)

New York State Teachers Retirement System decreased its position in Haemonetics Co. (NYSE:HAE) by 1.3% in the third quarter, HoldingsChannel.com reports. The fund owned 61,845 shares of the medical instruments supplier’s stock after selling 800 shares during the period. New York State Teachers Retirement System’s holdings in Haemonetics were worth $4,971,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Commonwealth Equity Services LLC raised its stake in shares of Haemonetics by 3.3% in the second quarter. Commonwealth Equity Services LLC now owns 3,673 shares of the medical instruments supplier’s stock worth $304,000 after purchasing an additional 117 shares during the last quarter. Vontobel Holding Ltd. raised its position in Haemonetics by 3.8% during the 3rd quarter. Vontobel Holding Ltd. now owns 4,878 shares of the medical instruments supplier’s stock worth $392,000 after buying an additional 180 shares during the last quarter. QRG Capital Management Inc. lifted its stake in Haemonetics by 6.9% during the 2nd quarter. QRG Capital Management Inc. now owns 4,031 shares of the medical instruments supplier’s stock valued at $333,000 after acquiring an additional 260 shares during the period. Arizona State Retirement System boosted its holdings in shares of Haemonetics by 2.0% in the 2nd quarter. Arizona State Retirement System now owns 14,217 shares of the medical instruments supplier’s stock valued at $1,176,000 after acquiring an additional 272 shares during the last quarter. Finally, Keene & Associates Inc. increased its stake in shares of Haemonetics by 3.0% in the third quarter. Keene & Associates Inc. now owns 10,174 shares of the medical instruments supplier’s stock worth $818,000 after acquiring an additional 298 shares during the period. Institutional investors and hedge funds own 99.67% of the company’s stock.

Haemonetics Stock Up 1.9 %

Shares of HAE opened at $74.93 on Wednesday. The firm has a market cap of $3.83 billion, a P/E ratio of 33.60, a PEG ratio of 1.12 and a beta of 0.32. Haemonetics Co. has a 12 month low of $70.25 and a 12 month high of $97.97. The stock’s 50 day moving average is $75.36 and its two-hundred day moving average is $82.63. The company has a current ratio of 3.76, a quick ratio of 2.33 and a debt-to-equity ratio of 1.35.

Haemonetics (NYSE:HAE) last released its quarterly earnings results on Thursday, August 8th. The medical instruments supplier reported $1.02 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.03 by ($0.01). The company had revenue of $336.17 million during the quarter, compared to analyst estimates of $335.08 million. Haemonetics had a net margin of 8.61% and a return on equity of 21.86%. Haemonetics’s revenue was up 8.0% compared to the same quarter last year. During the same period in the prior year, the business posted $1.05 EPS. Analysts predict that Haemonetics Co. will post 4.57 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the stock. CL King began coverage on shares of Haemonetics in a research report on Friday, September 13th. They set a “buy” rating and a $116.00 target price for the company. BTIG Research assumed coverage on Haemonetics in a report on Tuesday, September 10th. They issued a “buy” rating and a $112.00 price objective for the company. Bank of America initiated coverage on Haemonetics in a report on Wednesday, September 11th. They set a “neutral” rating and a $85.00 target price on the stock. Barrington Research reissued an “outperform” rating and issued a $108.00 price target on shares of Haemonetics in a report on Monday, September 23rd. Finally, JMP Securities restated a “market outperform” rating and issued a $125.00 price objective on shares of Haemonetics in a research report on Tuesday, August 13th. Three research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Haemonetics has a consensus rating of “Moderate Buy” and a consensus price target of $106.14.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.